Verve Therapeutics, Inc.
VERV
$6.16
-$0.16-2.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 271.44% | 174.98% | 219.91% | 279.70% | 379.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 271.44% | 174.98% | 219.91% | 279.70% | 379.79% |
| Cost of Revenue | 13.00% | 10.49% | 11.79% | 13.84% | 21.93% |
| Gross Profit | 11.37% | 0.68% | -2.34% | -4.88% | -13.92% |
| SG&A Expenses | 11.82% | 13.44% | 11.68% | 12.08% | 20.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.75% | 11.12% | 11.77% | 13.45% | 21.70% |
| Operating Income | 5.98% | -2.48% | -4.45% | -6.50% | -15.46% |
| Income Before Tax | 8.02% | 0.72% | -2.19% | -0.20% | -9.66% |
| Income Tax Expenses | -15.49% | 26.91% | 4.05% | 18.34% | 618.87% |
| Earnings from Continuing Operations | 8.04% | 0.68% | -2.19% | -0.22% | -9.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.04% | 0.68% | -2.19% | -0.22% | -9.84% |
| EBIT | 5.98% | -2.48% | -4.45% | -6.50% | -15.46% |
| EBITDA | 6.55% | -1.95% | -3.75% | -5.56% | -14.39% |
| EPS Basic | 26.65% | 25.06% | 20.64% | 18.15% | 8.45% |
| Normalized Basic EPS | 26.64% | 25.09% | 20.63% | 18.16% | 8.60% |
| EPS Diluted | 26.65% | 25.06% | 20.64% | 18.15% | 8.45% |
| Normalized Diluted EPS | 26.64% | 25.09% | 20.63% | 18.16% | 8.60% |
| Average Basic Shares Outstanding | 23.94% | 32.05% | 29.48% | 23.86% | 21.31% |
| Average Diluted Shares Outstanding | 23.94% | 32.05% | 29.48% | 23.86% | 21.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |